The Lipid Metabolism as Target and Modulator of BOLD-100 Anticancer Activity: Crosstalk with Histone Acetylation
- Author(s)
- Dina Baier, Theresa Mendrina, Beatrix Schoenhacker-Alte, Christine Pirker, Thomas Mohr, Mate Rusz, Benedict Regner, Martin Schaier, Nicolas Sgarioto, Noël J.M. Raynal, Karin Nowikovsky, Wolfgang M. Schmidt, Petra Heffeter, Samuel M. Meier-Menches, Gunda Koellensperger, Bernhard K. Keppler, Walter Berger
- Abstract
The leading first-in-class ruthenium-complex BOLD-100 currently undergoes clinical phase-II anticancer evaluation. Recently, BOLD-100 is identified as anti-Warburg compound. The present study shows that also deregulated lipid metabolism parameters characterize acquired BOLD-100-resistant colon and pancreatic carcinoma cells. Acute BOLD-100 treatment reduces lipid droplet contents of BOLD-100-sensitive but not -resistant cells. Despite enhanced glycolysis fueling lipid accumulation, BOLD-100-resistant cells reveal diminished lactate secretion based on monocarboxylate transporter 1 (MCT1) loss mediated by a frame-shift mutation in the MCT1 chaperone basigin. Glycolysis and lipid catabolism converge in the production of protein/histone acetylation substrate acetyl-coenzymeA (CoA). Mass spectrometric and nuclear magnetic resonance analyses uncover spontaneous cell-free BOLD-100-CoA adduct formation suggesting acetyl-CoA depletion as mechanism bridging BOLD-100-induced lipid metabolism alterations and histone acetylation-mediated gene expression deregulation. Indeed, BOLD-100 treatment decreases histone acetylation selectively in sensitive cells. Pharmacological targeting confirms histone de-acetylation as central mode-of-action of BOLD-100 and metabolic programs stabilizing histone acetylation as relevant Achilles’ heel of acquired BOLD-100-resistant cell and xenograft models. Accordingly, histone gene expression changes also predict intrinsic BOLD-100 responsiveness. Summarizing, BOLD-100 is identified as epigenetically active substance acting via targeting several onco-metabolic pathways. Identification of the lipid metabolism as driver of acquired BOLD-100 resistance opens novel strategies to tackle therapy failure.
- Organisation(s)
- Department of Inorganic Chemistry, Joint Metabolome Facility, Department of Analytical Chemistry, Mass Spectrometry Centre
- External organisation(s)
- Research Cluster Translational Cancer Therapy Research, University of Montreal, Veterinärmedizinische Universität Wien, Medizinische Universität Wien
- Journal
- Advanced science
- Volume
- 10
- ISSN
- 2198-3844
- DOI
- https://doi.org/10.1002/advs.202301939
- Publication date
- 11-2023
- Peer reviewed
- Yes
- Austrian Fields of Science 2012
- 301904 Cancer research
- Keywords
- ASJC Scopus subject areas
- Medicine (miscellaneous), General Chemical Engineering, General Materials Science, Biochemistry, Genetics and Molecular Biology (miscellaneous), General Engineering, General Physics and Astronomy
- Sustainable Development Goals
- SDG 3 - Good Health and Well-being
- Portal url
- https://ucrisportal.univie.ac.at/en/publications/63fdc0e9-9864-4481-a459-157457b8a1d0